1. Home
  2. NUWE vs GRI Comparison

NUWE vs GRI Comparison

Compare NUWE & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

N/A

Current Price

$3.77

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$1.20

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUWE
GRI
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.0M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
NUWE
GRI
Price
$3.77
$1.20
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $18.50
AVG Volume (30 Days)
★ 1.4M
38.8K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $8,270,000.00
N/A
Revenue This Year
$19.32
N/A
Revenue Next Year
$12.01
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.28
$0.18
52 Week High
$222.30
$64.12

Technical Indicators

Market Signals
Indicator
NUWE
GRI
Relative Strength Index (RSI) 40.20 34.98
Support Level $0.28 N/A
Resistance Level $5.74 $2.66
Average True Range (ATR) 0.51 0.18
MACD 0.02 -0.04
Stochastic Oscillator 0.86 2.16

Price Performance

Historical Comparison
NUWE
GRI

About NUWE Nuwellis Inc.

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: